207 related articles for article (PubMed ID: 15541129)
1. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial?
Black AM; Day AG; Morales A
BJU Int; 2004 Nov; 94(7):1066-70. PubMed ID: 15541129
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
3. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism.
Karazindiyanoğlu S; Cayan S
Aging Male; 2008 Sep; 11(3):146-9. PubMed ID: 18821291
[TBL] [Abstract][Full Text] [Related]
4. [Late-onset hypogonadism in men: uncertain disease entity and reservations regarding treatment with testosterone].
Nieuwenhuijzen Kruseman AC
Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1925-8. PubMed ID: 16999276
[TBL] [Abstract][Full Text] [Related]
5. Clinical practice experience with testosterone treatment in men with testosterone deficiency syndrome.
McLaren D; Siemens DR; Izard J; Black A; Morales A
BJU Int; 2008 Nov; 102(9):1142-6. PubMed ID: 18540933
[TBL] [Abstract][Full Text] [Related]
6. Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects.
Schubert M; Jockenhövel F
J Endocrinol Invest; 2005; 28(3 Suppl):23-7. PubMed ID: 16042356
[TBL] [Abstract][Full Text] [Related]
7. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function.
Chiang HS; Hwang TI; Hsui YS; Lin YC; Chen HE; Chen GC; Liao CH
Int J Impot Res; 2007; 19(4):411-7. PubMed ID: 17538639
[TBL] [Abstract][Full Text] [Related]
8. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.
Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ
Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499
[TBL] [Abstract][Full Text] [Related]
9. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
10. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
Morales A; Black AM; Emerson LE
BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790
[TBL] [Abstract][Full Text] [Related]
11. A comparison of anastrozole and testosterone versus placebo and testosterone for treatment of sexual dysfunction in men with epilepsy and hypogonadism.
Herzog AG; Farina EL; Drislane FW; Schomer DL; Smithson SD; Fowler KM; Dworetzky BA; Bromfield EB
Epilepsy Behav; 2010 Feb; 17(2):264-71. PubMed ID: 20096638
[TBL] [Abstract][Full Text] [Related]
12. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
13. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices.
Miner M; Canty DJ; Shabsigh R
Postgrad Med; 2008 Sep; 120(3):130-53. PubMed ID: 18824832
[TBL] [Abstract][Full Text] [Related]
14. Clinical and laboratoristic strategy in late onset hypogonadism.
Lombardo F; Lupini C; Meola A; Pallotti F; Gandini L; Lenzi A
Acta Biomed; 2010; 81 Suppl 1():85-8. PubMed ID: 20518196
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with Andriol Testocaps--the first Austrian surveillance study on the treatment of late-onset hypogonadism.
Jungwirth A; Plas E; Geurts P
Aging Male; 2007 Dec; 10(4):183-7. PubMed ID: 18033627
[TBL] [Abstract][Full Text] [Related]
16. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
18. Testosterone replacement therapy after primary treatment for prostate cancer.
Agarwal PK; Oefelein MG
J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
[TBL] [Abstract][Full Text] [Related]
19. 12-month observation of testosterone replacement effectiveness in a general population of men.
Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M
Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
[TBL] [Abstract][Full Text] [Related]
20. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
Moisey R; Swinburne J; Orme S
Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
